Antibody Access
Antibody Access - Related Videos
14:37
Accessibility to Clinical Care for People who use Wheelchairs
0 Views •
2023
Source: Yetsa Tuakli-Wosornu1,2, Jaideep Talwalkar1; 1Yale School of Medicine, 2University of Pittsburgh In the United States, 25% of the general population suffers from one or another type of disability. Ambulatory disabilities, or mobility impairments, represent the most common subcategory, comprising 14% of the country's populace. Different mobility-assistive devices, ranging from canes to scooters, enable increased independence and improved quality of life for those suffering from mobility...
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
01:10
Antibody Structure
0 Views •
2019
Overview Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding. The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains Antibodies consist of four polypeptide chains: two identical heavy...
11:56
Central Venous Access Device Dressing Change
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT Central venous access devices (CVAD), commonly known as central lines or central catheters, are large-bore intravenous (IV) catheters that are introduced into the central circulation. Typically, CVADs terminate in the superior vena cava, just outside of the right atrium of the heart, but they may also terminate in any one of the great veins (i.e., aorta, inferior vena cava, brachiocephalic...
FAQs
Fixation preserves cellular architecture, helping tissues and cells retain the structure needed for interpretation. Permeabilization then creates pathways through membranes or dense material, allowing antibodies to reach intracellular targets. These treatments serve different purposes, so effective immunostaining requires coordinating structural preservation with sufficient passage for antibodies to contact the relevant epitopes.
Increasing access can improve antibody penetration, but sample treatment must still preserve cellular shape and the target antigen. Researchers therefore optimize conditions rather than maximizing permeability alone. This balance matters because disrupted morphology can obscure localization, while altered antigen integrity can reduce the ability of antibodies to recognize the intended target.
Membranes, cellular architecture, and dense biological material can restrict movement toward intracellular epitopes. The extent of this structural limitation varies with the sample being examined, making access dependent on more than antibody binding itself. Treatments that create pathways through these barriers can improve staining of proteins located inside cells or within compact tissue regions.
Detergents or other permeabilization treatments create pathways through membranes and dense material. This improves the likelihood that antibodies can reach intracellular epitopes, which is especially important when the target lies inside a cell rather than at an exposed surface. Their use must be adjusted alongside fixation so access improves without sacrificing morphology or antigen integrity.
A practical approach begins by preserving the sample with fixation, followed by selecting a permeabilization treatment appropriate to its structure and target location. Researchers then assess whether antibody access supports clear, specific staining while retaining morphology and antigen integrity. Iterative optimization is useful because the best conditions depend on the sample and the intended immunostaining assay.
Improved access supports fluorescence microscopy, immunohistochemistry, and related assays that localize proteins in cells and tissues. Better penetration can strengthen the observable staining pattern and help distinguish where a target is located within biological structures. This makes access optimization relevant to studies of intracellular protein distribution as well as tissue-level organization.
Insufficient access can limit antibody contact with target molecules, producing weaker or incomplete localization information. Conditions that improve access can enhance signal quality and support more specific interpretation, provided morphology and antigen integrity remain preserved. Researchers therefore evaluate staining results in relation to both the observed signal and the structural quality of the sample.